Research progress of antithrombotic drugs

doi:10.16352/j.issn.1001-6325.2023.01.0183

Abstract

Abstract: Thrombosis is the main direct cause of acute manifestations of atherosclerotic cardiovascular disease (myocardial infarction, stroke). Globally, the incidence of thromboembolic diseases has increased in recent years, accompanied by an increase in patient mortality. Currently,several targeted drug delivery strategies have been developed for thromboembolic diseases, including antiplatelet drugs and anticoagulant drugs. With the development of antithrombotic drugs, the treatment of cardiovascular diseases caused by thrombus shows significant potential benefit for patients.

Key words: thrombus, drugs, antiplatelet, anticoagulant

CLC Number:

R364.1+5

ZHANG Jie, MA Xuzhou, LI Huihui, WANG Miao. Research progress of antithrombotic drugs[J]. Basic & Clinical Medicine, 2023, 43(1): 183-187.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: http://journal11.magtechjournal.com/Jwk_jcyxylc/EN/10.16352/j.issn.1001-6325.2023.01.0183

http://journal11.magtechjournal.com/Jwk_jcyxylc/EN/Y2023/V43/I1/183

References

[1] Mackman N, Bergmeier W, Stouffer GA,et al. Thera-peutic strategies for thrombosis: new targets and appro-aches[J]. Nat Rev Drug Discov, 2020,19: 333-352.
[2] 《中国心血管疾病与报告2020》编写组.《中国心血管疾病与健康》要点解读[J]. 中国心血管杂志, 2021, 26: 209-218.
[3] Roth GA,Mensah GA,Johnson CO.et al.Global burden of cardiovascular diseases and risk factors, 1990—2019: update from the GBD 2019 Study[J].J Am Coll Cardiol, 2020, 76: 2982-3021.
[4] Badimon L, Vilahur G. Thrombosis formation on atherosclerotic lesions and plaque rupture[J]. J Intern Med, 2014, 276: 618-632.
[5] Thompson AE. Deep vein thrombosis[J]. JAMA, 2015, 313: 2090-2090.
[6] Baqi Y,Muller CE.Antithrombotic P2Y12 receptor antagonists: recent developments in drug discovery[J]. Drug Discov Today,2019, 24:325-333
[7] Zwart B, Parker WAE, Storey RF. New antithrombotic drugs in acute coronary syndrome[J]. J Clin Med, 2020, 9: 2059-2077.
[8] Capodanno D, Angiolillo DJ.Antithrombotic therapy for atherosclerotic cardiovascular disease risk mitigation in patients with coronary artery disease and diabetes mellitus[J]. Circulation,2020, 142:2172-2188.
[9] Patrono CM, Baigent C, Collet J,et al. Antiplatelet agents for the treatment and prevention of coronary atherothrombosis[J]. JAmCollCardiol, 2017, 70: 1760-1776.
[10] Barra ME, Fanikos J, Connors JM, et al. Evaluation of dose-reduced direct oral anticoagulant therapy[J]. Am J Med, 2016, 129: 1198-1204.
[11] Warkentin TE, Pai M, and Linkins LA. Direct oral anticoagulants for treatment of HIT: update of Hamilton experience and literature review[J]. Blood, 2017, 130: 1104-1113.
[12] Schüpke S,Hein-Rothweiler S,Mayer K, et al. Revacept, a novel inhibitor of platelet adhesion, in patients undergoing elective pci-design and rationale of the randomized isar-plaster trial[J]. Thromb Haemost, 2019, 119: 1539-1545.
[13] Mayer K, Hein-Rothweiler R, Schüpke S, et al. Efficacy and safety of revacept, a novel lesion-directed competitive antagonist to platelet glycoprotein vi, in patients undergo-ing elective percutaneous coronary intervention for stable ischemic heart disease: the randomized, double-blind, placebo-controlled isar-plaster phase 2 trial[J]. JAMA Cardiol, 2021, 6: 753-761.
[14] Mackman N, Bergmeier W, Stouffer GA, et al.Therapeu-tic strategies for thrombosis: new targets and approaches[J]. Nat Rev Drug Discov 2020, 19: 333-352.
[15] Morrow DA, Braunwald E, Bonaca MP, et al. Vorapaxar in the secondary prevention of atherothrombotic events[J]. N Engl J Med, 2012, 366: 1404-1413.
[16] Suehiro E, Fujiyama Y, Kiyohira M, et al. Risk of deterioration of geriatric traumatic brain injury in patients treated with antithrombotic drugs[J].World Neurosurg,2019, 127:e1221-e1227.
[17] Weitz JI,Chan NC. Novel antithrombotic strategies for treatment of venous thromboembolism[J]. Blood, 2020, 135: 351-359.
[18] Lorentz CU, Verbout NG, Wallisch M,et al.Contact activation inhibitor and factor Ⅺ antibody, ab023, produces safe, dose-dependent anticoagulation in a phase 1 first-in-human trial[J]. Arterioscler Thromb Vasc Biol, 2019, 39: 799-809.
[19] Koch AW, Schiering N, Melkko S, et al.MAA868, a novel FXI antibody with a unique binding mode, shows durable effects on markers of anticoagulation in humans[J]. Blood, 2019, 133: 1507-1516.
[20] Pireaux V, Tassignon J, Demoulin S, et al. Anticoagula-tion with an inhibitor of factors Ⅺa and Ⅻa during cardiopulmonary bypass[J]. J Am Coll Cardiol, 2019, 74: 2178-2189.
[21] Bauml M, Hilgendorf I. Future antithrombotic therapies in cardiology[J]. Hamostaseologie, 2018, 38: 236-239.
[22] Bielecki S, Lee D,Hamad B. The market for oral anticoagulants[J]. Nat Rev Drug Discov, 2018, 17: 617-618.